Pharmacy Department, IU Health Bloomington Hospital, 2651 E. Discovery Parkway, Bloomington, IN 47408, United States.
Pharmacy Department, IU Health Bloomington Hospital, 2651 E. Discovery Parkway, Bloomington, IN 47408, United States.
Am J Emerg Med. 2022 Aug;58:79-83. doi: 10.1016/j.ajem.2022.05.036. Epub 2022 May 25.
Procedural sedation for electrical cardioversion is a common practice in the emergency department (ED). Ideal sedative properties for this procedure are a short half-life and minimal hemodynamic effects. There is limited literature examining methohexital for this use.
To compare the use of methohexital to propofol and etomidate for procedural sedation for electrical cardioversions in the ED.
This was a single-center, retrospective study of adult patients who underwent procedural sedation for electrical cardioversion in the ED between February 1, 2015 and July 31, 2020. Included patients received methohexital, propofol, or etomidate as an initial sedative agent in the ED. The primary outcome was time from initial dose of sedative to goal Aldrete score. The main secondary outcome was time from sedative agent to ED discharge. The safety outcome was the occurrence of a critical hemodynamic change requiring intervention. Outcomes were assessed using a single-factor ANOVA analysis.
One-hundred and fifty cardioversion encounters were included with 50 encounters per cohort. The median (IQR) time (minutes) to goal Aldrete score was 10.5 (7-18.5) for methohexital, 12.0 (9-16.8) for propofol, and 11.0 (8-15) for etomidate (p = 0.863). Mean (SD) time (minutes) to discharge from the ED (n = 105) was 90.4 ± 40.4 for methohexital, 89.0 ± 57.4 for propofol, and 94.0 ± 42.5 for etomidate (p = 0.897). No difference was seen between the groups regarding hemodynamic changes requiring intervention.
Methohexital was found to have a similar efficacy and safety profile when compared to propofol and etomidate when used as procedural sedation for cardioversions in the ED.
在急诊科(ED),电复律的程序镇静是一种常见的做法。这种程序的理想镇静特性是半衰期短和最小的血液动力学影响。目前,关于美索比妥在这方面的应用的文献有限。
比较美索比妥、丙泊酚和依托咪酯在 ED 中用于电复律程序镇静的效果。
这是一项单中心、回顾性研究,纳入 2015 年 2 月 1 日至 2020 年 7 月 31 日期间在 ED 接受电复律程序镇静的成年患者。纳入的患者在 ED 中接受美索比妥、丙泊酚或依托咪酯作为初始镇静剂。主要结局是从初始镇静剂量到目标 Aldrete 评分的时间。主要次要结局是从镇静剂到 ED 出院的时间。安全性结局是出现需要干预的关键血液动力学变化。结果使用单因素方差分析进行评估。
共纳入 150 次电复律,每个队列 50 次。美索比妥组达到目标 Aldrete 评分的中位数(IQR,分钟)为 10.5(7-18.5),丙泊酚组为 12.0(9-16.8),依托咪酯组为 11.0(8-15)(p = 0.863)。从 ED 出院的平均(SD)时间(分钟)(n = 105)为美索比妥组 90.4 ± 40.4,丙泊酚组 89.0 ± 57.4,依托咪酯组 94.0 ± 42.5(p = 0.897)。在需要干预的血液动力学变化方面,三组之间没有差异。
在 ED 中,美索比妥在用于电复律的程序镇静时,与丙泊酚和依托咪酯相比,其疗效和安全性相当。